

## NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE CASE CONTROL STUDIES

### Review: diabetes and chemotherapy-induced peripheral neuropathy (CIPN)

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.

#### Selection

- 1) Is the case definition adequate?
  - a) yes, with independent validation (eg. doctor's diagnosis, reference to primary record source) \*
  - b) yes, eg record linkage or based on self reports
  - c) no description
- 2) Representativeness of the cases
  - a) consecutive or obviously representative series of cases \*
  - b) potential for selection biases or not stated
- 3) Selection of Controls
  - a) community controls (same community as cases) \*
  - b) hospital controls
  - c) no description
- 4) Definition of Controls
  - a) no history of disease (endpoint) \*
  - b) no description of source

#### Comparability

- 5) Comparability of cases and controls on the basis of the design or analysis
  - a) study controls for cumulated dose of antineoplastic agents \*
  - b) study controls for age, sex, type of antineoplastic agents, duration of treatment, race, type of cancer, Eastern Cooperative Oncology Group (ECOG) performance status, etc. \*

#### Exposure

- 6) Ascertainment of exposure
  - a) secure record (eg. doctor's diagnosis, objective measurements) \*
  - b) structured interview where blind to case/control status \*
  - c) interview not blinded to case/control status
  - d) written self report or medical record only
  - e) no description
- 7) Same method of ascertainment for cases and controls
  - a) yes \*
  - b) no
- 8) Non-Response rate
  - a) same rate for both groups \*
  - b) non respondents described
  - c) rate different and no designation